Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to lower symptomatic PE compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic DVT compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower any VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with no thromboprophylaxis (low certainty).
1 finding from 1 review
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher clinically relevant bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic VTE compared with with active control (1) (low certainty).
3 findings from 1 review
RR 2.89 [0.12, 66.75]
1 study · 51 participants
Low
RR 0.51 [0.22, 1.17]
2 studies · 781 participants
Moderate
RR 0.33 [0.14, 0.83]
1 study · 439 participants
High
Major bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with with active control (1); GRADE not reported.
3 findings from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin showed no clear difference in any VTE compared with with active control (1); GRADE not reported.
3 findings from 1 review
RR 4.81 [0.24, 95.58]
Studies not reported
GRADE not reported
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Clinically relevant bleeding · ambulatory cancer patients receiving chemotherapy
The review found no eligible studies for this question.
3 findings from 1 review
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
no estimate extracted
Studies not reported
No studies found
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin leads to lower symptomatic VTE compared with no thromboprophylaxis (high certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Low‐molecular‐weight heparin probably leads to higher major bleeding compared with no thromboprophylaxis (moderate certainty).
1 finding from 1 review
Symptomatic VTE · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic VTE compared with placebo (high certainty).
1 finding from 1 review
Major bleeding · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in major bleeding compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic PE · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in symptomatic PE compared with placebo (moderate certainty).
1 finding from 1 review
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
1 finding from 1 review
Total VTE · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower any VTE compared with placebo (high certainty).
1 finding from 1 review
1‐year overall mortality · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin showed no clear difference in 1‐year overall mortality compared with placebo (moderate certainty).
1 finding from 1 review